Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLM3004 for Myopia Progression in Children
NCT06151587Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QLM3004 in myopia (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Change from Baseline in spherical equivalent determined by cycloplegic autorefraction at 96 weeks. Started Aug 2023; status: recruiting.
02
Drugs
QLM3004
03
Conditions
myopia
Beyond the preview
Go deeper on NCT06151587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151587.